22 Jan Sensorion
Valérie Salentey, Regulatory Affairs and Quality Assurance Director
April 9 | 5:00pm | Salone dei Cavalieri, Section 2
Paris, France
(NASDAQ: ALSEN)
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It develops two gene therapy programs (SENS-501 and GJB2-GT) aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation.
